#SARSCoV2 mRNA vaccine development enabled by prototype pathogen preparedness
A SARS-CoV-2 vaccine is needed to control the global COVID-19 public health crisis. Atomic-level structures directed the application of prefusion-stabilizing mutations that improved expression and immunogenicity of betacoronavirus spike proteins. Using this established immunogen design, the release of SARS-CoV-2 sequences triggered immediate rapid manufacturing of an mRNA vaccine expressing the prefusion-stabilized SARS-CoV-2 spike trimer (mRNA-1273). Here, we show that mRNA-1273 induces both potent neutralizing antibody and CD8 T cell responses and protects against SARS-CoV-2 infection in lungs and noses of mice without evidence of immunopathology. mRNA-1273 is currently in a Phase 2 clinical trial with a trajectory towards Phase 3 efficacy evaluation.
#Coronavirus may have mutated to become more infectious: Fauci1027Yesterday, 04:05
There are now 141 vaccines in development. #WHO157702.07.2020, 17:40
#WHO's Ryan: more than 133 #coronavirus vaccine candidates put Into system212330.06.2020, 17:25
Fauci says #COVID_19 vaccine may not get US to herd immunity if too many people refuse to get it230730.06.2020, 00:05
CanSino's #COVID_19 #vaccine candidate approved for military use in China216829.06.2020, 17:25
#Google will now auto-delete location and search history by default for new users264926.06.2020, 00:10